Molecular epidemiology of hepatitis C virus strains from Romania

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 3, 2011, Pages 261-266

  Sultana, Camelia ^a   Oprisan, Gabriela ^a   Szmal, Camelia ^a   Vagu, Codruta ^a   Temereanca, Aura ^a   Dinu, Sorin ^a   Teleman, Monica Delia ^a   Ruta, Simona ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Genotyping methods; Hepatitis C virus; Molecular epidemiology; Risk factors

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD TRANSFUSION; BODY PIERCING; CONTROLLED STUDY; DENTAL SURGERY; ESTHETIC SURGERY; EUROPE; FEMALE; GENOTYPE; GEOGRAPHIC PATHOLOGY; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INFUSION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MOLECULAR EPIDEMIOLOGY; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; RETROSPECTIVE STUDY; ROMANIA; SEX RATIO; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ADULT; AGED; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; RETROSPECTIVE STUDIES; ROMANIA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 80053497679     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 2007; 13: 4808-4817.
2. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-355.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
4. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
5. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
6. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
7. Thomas D, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
8. Raimondi S, Bruno S, Mondelli M, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis. J Hepatol 2009; 50: 1142-1154.
9. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-115.
10. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-122.
11. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis 2010; 19: 373-379.
12. Grigorescu M; Romanian Society of Gastroenterology and Hepatology. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis 2009; 18: 45-50.
13. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162.
14. Oprisan G, Szmal C, Dinu S, et al. Comparative methods for genotyping hepatitis C virus isolates from Romania. Roum Arch Microbiol Immunol 2009; 68: 151-157.
15. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599.
16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and National Antidrug Agency from Romania (NAA). National Report on Drugs Situation for Romania, New Developments, Trends and In-depth Information on Selected Issues. Bucharest: REITOX, 2010.
17. Simmonds P, Mellor J, Sakuldamrongpanich T, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifcations based upon sequence similarity. J Gen Virol 1996; 77: 3013-3024.
18. Colina R, Casane D, Vasquez S, et al. Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 2004; 85: 31-37.
19. Kalinina O, Norder H, Magnius LO. Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J Gen Virol 2004; 85: 1853-1857.
20. Cochrane A, Searle B, Hardie A, et al. A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis 2002; 186: 1212-1221.
21. Haushofer AC, Kopty C, Hauer R, Brunner H, Halbmayer WM. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol 2001; 20: 41-47.
22. Huppe D, Zehnter E, Mauss S, et al. Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centers and outpatient units. Z Gastroenterol 2008; 46: 34-44.
23. Wiese M, Grüngreiff G, Güthoff, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. J Hepatol 2005; 43: 590-598.
24. Cenci M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes in central Italy. Anticancer Res 2003; 23: 5129-5132.
25. Nemecek V, Strunecký O. Genotypic heterogeneity of hepatitis C virus (HCV) from blood donors in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 63-72.
26. Chlabicz S, Flisiak R, Kowalczuk O, et al. Changing HCV genotypes distribution in Poland - relation to source and time of infection. J Clin Virol 2008; 42: 156-159.
27. Gazdik F, Gazdikova K, Laktis K, et al. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. Bratisl Lek Listy 2009; 110: 77-84.
28. Paintsil E, Verevochkin SV, Dukhovlinova E, et al. Hepatitis C virus infection among drug injectors in St. Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009; 104: 1881-1890.
29. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
30. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: fnal results of phase 3 ADVANCE study. Hepatology 2010; 52: 427A.
31. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49: 1838-1846.
32. Gheorghe L, Pascu O, Ceausu E, et al. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009. J Gastrointestin Liver Dis 2010; 19: 161-167.
33. Pascu O, Gheorghe L, Voiculescu M, Ceausu E, Mateescu B. How severe is chronic hepatitis with HCV genotype 1b? A study of 1,220 cases on the waiting list for antiviral therapy in Romania. J Gastrointestin Liver Dis 2011; 20: 51-55.